Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $231.83 | 4 | 60.7% |
| Unspecified | $150.00 | 1 | 39.3% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $184.45 | 1 | $0 (2023) |
| Indivior Inc. | $150.00 | 1 | $0 (2020) |
| AbbVie Inc. | $30.25 | 2 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $17.13 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $184.45 | 1 | Abbott Laboratories ($184.45) |
| 2021 | $30.25 | 2 | AbbVie Inc. ($30.25) |
| 2020 | $150.00 | 1 | Indivior Inc. ($150.00) |
| 2019 | $17.13 | 1 | Teva Pharmaceuticals USA, Inc. ($17.13) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2023 | Abbott Laboratories | MITRACLIP (Device) | Food and Beverage | In-kind items and services | $184.45 | General |
| Category: Vascular | ||||||
| 08/24/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: NEUROSCIENCE | ||||||
| 03/09/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: NEUROSCIENCE | ||||||
| 07/21/2020 | Indivior Inc. | BUPRENORPHINE AND NALOXONE (Drug), SUBOXONE | — | Cash or cash equivalent | $150.00 | Research |
| Study: Quantitative Testing of Prescriber/Pharmacist Knowledge, Attitudes and Behavior about SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) or the Authorized Generic of SUBOXONE Sublingual Film (CIII) Safety and Use Information • Category: OUD | ||||||
| 09/18/2019 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Central Nervous System | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Quantitative Testing of Prescriber/Pharmacist Knowledge, Attitudes and Behavior about SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) or the Authorized Generic of SUBOXONE Sublingual Film (CIII) Safety and Use Information | Indivior Inc. | $150.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 847 | 1,140 | $485,593 | $75,925 |
| 2022 | 20 | 719 | 908 | $316,014 | $57,620 |
| 2021 | 17 | 598 | 780 | $221,712 | $46,950 |
| 2020 | 17 | 547 | 685 | $197,700 | $39,823 |
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 116 | 184 | $90,712 | $20,668 | 22.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 68 | 68 | $11,900 | $11,138 | 93.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 100 | 142 | $48,990 | $9,044 | 18.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 42 | $29,064 | $6,980 | 24.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 35 | 35 | $82,005 | $5,535 | 6.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 38 | $22,002 | $4,788 | 21.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 39 | $15,795 | $3,243 | 20.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 12 | 12 | $27,012 | $2,815 | 10.4% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $26,741 | $1,955 | 7.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 14 | 14 | $8,624 | $1,676 | 19.4% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 14 | 14 | $22,017 | $1,500 | 6.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 93 | 136 | $21,352 | $1,384 | 6.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 15 | 15 | $28,965 | $1,092 | 3.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 81 | 126 | $11,088 | $953.23 | 8.6% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 61 | 65 | $7,150 | $849.52 | 11.9% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 35 | 45 | $9,360 | $740.70 | 7.9% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 30 | 47 | $6,204 | $447.44 | 7.2% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 19 | 19 | $3,914 | $359.48 | 9.2% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 11 | 13 | $2,678 | $234.26 | 8.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 18 | 19 | $4,427 | $211.65 | 4.8% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 18 | 22 | $2,486 | $182.38 | 7.3% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 13 | 19 | $2,147 | $96.52 | 4.5% |
| 81003 | Automated urinalysis test | Office | 2023 | 12 | 15 | $960.00 | $33.00 | 3.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 99 | 142 | $53,139 | $14,756 | 27.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 58 | 58 | $10,095 | $9,812 | 97.2% |
About Dr. Daniel Kim, MD
Dr. Daniel Kim, MD is a Family Medicine healthcare provider based in Juneau, Alaska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1194870063.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Kim, MD has received a total of $381.83 in payments from pharmaceutical and medical device companies, with $184.45 received in 2023. These payments were reported across 5 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($231.83).
As a Medicare-enrolled provider, Kim has provided services to 2,711 Medicare beneficiaries, totaling 3,513 services with total Medicare billing of $220,318. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Juneau, AK
- Active Since 01/23/2007
- Last Updated 02/26/2013
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1194870063
Products in Payments
- MITRACLIP (Device) $184.45
- BUPRENORPHINE AND NALOXONE (Drug) $150.00
- UBRELVY (Drug) $30.25
- AUSTEDO (Drug) $17.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Juneau
Myanandi Than, M.d, M.D
Family Medicine — Payments: $1,115
Janice Heaton-Sheufelt, Md, MD
Family Medicine — Payments: $166.02
Dr. Mignon Benjamin, Md, MD
Family Medicine — Payments: $153.71
Joseph Roth, M.d, M.D
Family Medicine — Payments: $150.00
Dr. Robert Haight, Md, MD
Family Medicine — Payments: $146.33
Richard Welling
Family Medicine — Payments: $132.54